To hear about similar clinical trials, please enter your email below
Trial Title:
Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors
NCT ID:
NCT06332755
Condition:
Non-small Cell Lung Cancer(NSCLC)
Head and Neck Squamous Cell Carcinoma(HNSCC)
Renal Cell Carcinoma(RCC)
Urothelial Carcinoma
Malignant Melanoma
Conditions: Official terms:
Carcinoma
Melanoma
Carcinoma, Renal Cell
Squamous Cell Carcinoma of Head and Neck
Conditions: Keywords:
solid tumor
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Sequential Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
LB-LR1109
Description:
intravenous administration
Arm group label:
Dose Escalation
Summary:
This is a Phase 1, first-in-human (FIH), multi-center, open-label, non-randomized, dose
escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase
2 dose(RP2D) of LB-LR1109 and to evaluate safety, tolerability, preliminary efficacy,
pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109, and its impact on
quality of life in participants with unresectable and metastatic nonsmall cell lung
cancer(NSCLC), head and neck squamous cell carcinoma(HNSCC), renal cell carcinoma(RCC),
urothelial carcinoma, or malignant melanoma and no available standard of care treatment
options.
Criteria for eligibility:
Criteria:
Key Inclusion Criteria:
1. Age ≥18 years old at the time of signing the ICF.
2. Participants must have 1 of the following histologically confirmed advanced or
metastatic solid tumors with measurable or non-measurable disease as determined by
RECIST v1.1,
- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.
3. Participants who have metastatic disease which has progressed during or after
approved standard therapies or are intolerant to all approved therapies, or for
which the participant refuses or is ineligible for standard therapy.
4. Able to submit the most recently obtained archival tumor tissue
5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
6. Life expectancy ≥12 weeks.
7. Participants with adequate organ function
8. No potential for childbearing or agree to use adequate contraception
9. Ability to understand the study purpose and procedures and have the willingness to
sign a written informed consent document.
Key Exclusion Criteria:
1. Clinically significant cardiac disease or cardiac failure.
2. Untreated or unstable brain or central nervous system (CNS) metastases or
Leptomeningeal disease
3. Participants with any concurrent active malignancies
4. Prior LILRB or immunoglobulin-like transcript targeting therapy previously.
5. History of life-threatening toxicity related to prior immune therapy
6. Has not recovered to ≤ Grade 1 or baseline from AEs (except for toxicities not
considered a safety risk such as alopecia, or asymptomatic laboratory abnormalities)
due to prior therapy and/or complications from prior surgical intervention or any
anti-cancer treatment before starting study treatment.
7. Participants must not have an active, known, or suspected autoimmune disease.
8. Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to
initiation of study treatment therapy (does not apply to viral infections that are
presumed to be associated with the underlying tumor type required for study entry).
9. Pregnant or lactating or expecting to conceive a child during the study or within 6
months after the last dose of study intervention.
10. Any condition that would, in the Investigator's judgment, interfere with full
participation in the study, including administration of study intervention and
attending required study visits; pose a significant risk to the participant; or
interfere with interpretation of study data.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
NEXT Oncology
Address:
City:
Fairfax
Zip:
22031
Country:
United States
Status:
Recruiting
Contact:
Last name:
Alexander Spirra
Phone:
703-783-4508
Email:
alexander.spira@usoncology.com
Start date:
June 5, 2024
Completion date:
February 2027
Lead sponsor:
Agency:
LG Chem
Agency class:
Industry
Source:
LG Chem
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06332755